Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

Cardiol Therapeutics (TSX: CRDL) (NYSE: CRDL) has released topline results from their phase two ARCHER trial targeting ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...

City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

Researchers at the University of New Mexico are preparing to launch a phase 1 clinical trial for an Alzheimer's vaccine after ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

The first patient in the U.S. has been dosed with a novel radioactive medicine to treat advanced breast cancer as part of an international clinical trial.